Prime Medicine, Inc. (NASDAQ:PRME) is a biotechnology company at the forefront of gene editing technology, focusing on developing treatments for serious genetic diseases. With a market capitalization ...
In a major shift, Editas has pivoted its focus towards in vivo gene editing, particularly targeting liver and hematopoietic stem cells (HSCs). This strategic move comes after the company terminated ...
Editas Medicine, Inc. (NASDAQ:EDIT), a biotechnology company specializing in transformative gene editing therapies, has been making significant strides in its strategic focus on cardiometabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results